Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Follow-Up Questions
Who is the CEO of Aspire Biopharma Holdings Inc?
Mr. Surendra Ajjarapu is the Executive Chairman of the Board of Aspire Biopharma Holdings Inc, joining the firm since 2023.
What is the price performance of ASBP stock?
The current price of ASBP is $0.4452, it has increased 1.11% in the last trading day.
What are the primary business themes or industries for Aspire Biopharma Holdings Inc?
Aspire Biopharma Holdings Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Aspire Biopharma Holdings Inc market cap?
Aspire Biopharma Holdings Inc's current market cap is $22.0M